Quality Assistance strengthens its presence in the United States during the Belgian Economic Mission to the West Coast
From 6 to 12 October 2025, we proudly participated in the Belgian Economic Mission to the United States (West Coast), led by Her Royal Highness Princess Astrid of Belgium.
Our participation, headed by Nathalie Draux, CEO, together with Pierre Baudoux, Senior Sales Manager, and Julie Jia, Business Developer, underlined our strong commitment to expanding and strengthening ties with US biopharma and biotech companies.
This economic mission was the perfect opportunity to reaffirm our ambition: connecting European and American pharmaceutical innovation through analytical excellence. This mission highlights how our expertise in analytical sciences, rooted in our values of respect, excellence and commitment, contributes to accelerating access to tomorrow’s life-changing therapies through analytical excellence and trusted partnership.
Driving transatlantic collaboration in the life sciences sector
Throughout this week bringing together leaders from Belgium and influential players in the Californian life science ecosystem, our focus was clear:
- Connecting with US biopharma and biotech innovators: California, from the Silicon Valley to San Diego, hosts an exceptional concentration of companies developing biotherapeutics, viral vectors, mRNA, cell and gene therapies. Engaging directly with these companies allows us to better understand their scientific priorities and analytical challenges
- Present our unique single-site analytical model, supported by a full GxP compliance (GMP, GLP, GcLP/GCP) environment and a strong quality system: our integrated site in Belgium ensures faster turnaround, data consistency, and no inter-site variability, a key advantage for companies navigating complex regulatory landscapes
- Support US companies seeking efficient, compliant access to the European market: our dual EMA + FDA regulatory expertise enables seamless analytical pathways for transatlantic development programmes.
A major milestone: strengthening our partnership with Eyconis
A key highlight of the mission was the signing of a Letter of Intent with Eyconis, Inc., reinforcing the collaboration initiated in March 2024 around the clinical development of their innovative ophthalmic product, EYC-0305.
The signing took place during the official ceremony attended by HRH Princess Astrid of Belgium and Californian Governor Gavin Newsom, reflecting the importance of cooperation between Europe and the United States.
During the next phase of this collaboration, we will provide:
- GMP batch release testing,
- stability studies
- and advanced analytical support based on more than 20 orthogonal analytical methods, combining product-specific and compendial techniques.
This collaboration is the perfect illustration of how rigorous scientific expertise, reliable methods and effective communication can help bring promising therapeutics one step closer to the patients.
Building the next chapter of US–EU analytical collaboration
Our participation in the Belgian Economic Mission represented a significant step in our long-term strategy to support US biotech and pharmaceutical companies with robust, compliant and efficient analytical solutions.
From early development to clinical phases and registration, we act as a trusted precision partner for teams bringing innovative therapies to patients worldwide.